Aug 2026· JACC: Advances· pp.
103134
· 0 citations· 33 references
Medicine
TL;DR
Current evidence remains insufficient to establish a cardiovascular benefit of PPV23, and further adequately powered evidence is needed to resolve the remaining uncertainty.
Abstract
Background
Prior observational studies have suggested that 23-valent pneumococcal polysaccharide vaccination (PPV23) may be associated with lower cardiovascular risk, but whether this association persists in randomized trials and adjusted observational studies remains uncertain.
Objectives
This study evaluated whether PPV23 vaccination is associated with reduced risk of acute coronary syndrome (ACS) events, stroke, and all-cause mortality using evidence from randomized trials and propensity-adjusted observational studies.
Methods
MEDLINE, Embase, and Cochrane CENTRAL were systematically searched from inception to October 10, 2025. The authors included randomized controlled trials and observational cohort studies using propensity-based adjustment that compared PPV23 with placebo or no vaccination and reported ACS events, stroke, or all-cause mortality. Two reviewers independently extracted data and assessed risk of bias. Random-effects Bayesian and frequentist meta-analyses were used to pool HRs with 95% credible intervals (CrIs) or CIs.
Results
Six studies, including 2 randomized trials and 4 propensity-adjusted cohort studies were included. In the Bayesian analysis, the pooled HR for ACS events was 0.87 (95% CrI: 0.64-1.14), corresponding to an 85% posterior probability of any benefit, although the CrI and prediction interval indicated substantial uncertainty. Bayesian estimates did not suggest benefit for stroke (HR: 1.10; 95% CrI: 0.83-1.48) or all-cause mortality (HR: 1.02; 95% CrI: 0.83-1.29). Frequentist analyses were directionally consistent, with 95% CIs crossing the null for ACS events, stroke, and all-cause mortality. The certainty of evidence by Grading of Recommendations Assessment, Development and Evaluation was low across all outcomes.
Conclusions
Current evidence remains insufficient to establish a cardiovascular benefit of PPV23. Further adequately powered evidence is needed to resolve the remaining uncertainty.
INTRODUCTION
Older adults face an increased risk of influenza-related complications, particularly cardiovascular (CV) events. The comparative effectiveness of high-dose inactivated influenza vaccine (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) for these outcomes remains uncertain.
METHODS
Data...
Larissa Araújo de Lucena, B. Hakkeem, N. Schettino Samad et al.· American Journal of Preventi...· 0 citations
PCSK9-targeting therapies were associated with lower all-cause mortality and fewer ischemic events across trial populations, and the predominant contribution of large cardiovascular outcome trials enrolling populations with known atherosclerosis and using PCSK9 antibodies limits the ability to infer a survival benefit.
E. Navarese, E. Ruscio, Hai-Xiang Zheng et al.· European Journal of Preventi...· 0 citations
Background: The role of statins for primary cardiovascular prevention in older adults with hypertension but without established cardiovascular disease remains uncertain. This systematic review and meta-analysis evaluated the effectiveness and safety of statin therapy in this population.
Methods: PubMed, Scopus, Web of...
Waleed Almalki, Bashar Aljadani, Fatimah M. Alsalhi et al.· Annals of Middle Eastern Med...· 0 citations
Patients with chronic immune-mediated disorders (IMIDs), including inflammatory bowel disease (IBD), are at increased risk of cardiovascular disease. While advanced therapies show cardioprotective effects in other IMIDs, their impact on major adverse cardiovascular events (MACE) in IBD remains unclear. We conducted a m...
A. Alnahdi, C. Salmon, F. Du et al.· Inflammation Research· 1 citation
Statins are foundational therapy for cardiovascular prevention; however, up to 50% of patients discontinue treatment within one year. Randomized trials show similar adverse event rates in statin and placebo groups, suggesting that nocebo effects contribute substantially to perceived intolerance and non-adherence....
H. Hayrapetyan, M. Sargsyan, V. R. Ter-Grigoryan et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.